ACTOVEGIN 200mg 5 Injections Takeda - pack of 4 boxes - 20 vials
Price: 240$ 
e-mail: sales@gerovital-gh3.com
 
 
Indications:
Prophylaxis and treatment of cerebral circulatory and trophic disorders (ischemic stroke, treatment of craniocerebral trauma).
Prophylaxis and treatment of peripheral vascular diseases (arterial or venous) and their sequelae (arterial angiopathy and varicose ulcer).
Treatment of skin grafts.
Treatment of burns, skin erosions and lesions caused by contact with hot liquids.
Treatment of wounds in patients with impaired recovery: torpid skin or mucosal ulcers and decubitus ulcers.
Prophylaxis and treatment of skin-mucosal lesions induced by radiotherapy.
Contraindications:
Do not use Actovegin:
- if you are allergic to deproteinized hemoderivate from calf blood or to any of the other components of this medicine.
Precautions:
Before using Actovegin, consult your doctor or pharmacist.
Pregnancy, breast-feeding and fertility:
If you are pregnant or breast-feeding, think you may be pregnant or are planning to become pregnant, ask your doctor or pharmacist for advice before taking this medicine.
The use of Actovegin in humans has not shown any negative effects on the mother or the child. However, the therapeutic benefits of Actovegin must be weighed against the possible risks to the child.
Driving and using machines:
Actovegin does not affect the ability to drive or use machines.
Method of administration:
Always use this medicine exactly as your doctor or pharmacist has told you. Talk to your doctor or pharmacist if you are not sure.
Dosage:
Actovegin - injection solution is administered intravenously, intramuscularly or intraarterially and is added to infusion solutions.
a) General indications for administration:
Treatment with Actovegin is adjusted depending on the severity of the clinical picture. Treatment is initiated with 400-800 mg of deproteinized calf blood hemoderivative (10-20 ml of Actovegin injection solution) per day, administered intravenously, intraarterially or by infusion. In maintenance therapy, 200 mg of deproteinized calf blood hemoderivative (5 ml of Actovegin injection solution) is administered intravenously daily or slowly intramuscularly several times a week.
For infusion administration, 400-2000 mg of deproteinized calf blood hemoderivative (10-50 ml of Actovegin injection solution) is added to 200-300 ml of base solution (isotonic NaCl solution or 5% glucose solution). The administration rate is approximately 2 ml per minute.
b) Dosage according to indication:
Cerebral circulatory and trophic disorders: the recommended initial dose is 400 mg of deproteinized hemoderivative from calf blood (10 ml of Actovegin injectable solution) per day, administered intravenously for two weeks, then continue with 200-400 mg of deproteinized hemoderivative from calf blood (5-10 ml of Actovegin injectable solution) administered intravenously several times a week, for 4 weeks.
Ischemic cerebrovascular accidents: the recommended dose is 800-2000 mg of deproteinized hemoderivative from calf blood (20-50 ml of Actovegin injectable solution), administered by infusion in 200-300 ml of base solution, daily or several times a week, for two-three weeks.
Arteriopathies: the recommended dose is 800-2000 mg of deproteinized hemoderivative from calf blood (20-50 ml of Actovegin injection solution), administered by infusion, intraarterially or intravenously, daily or several times a week, for four weeks.
Treatment of varicose ulcers or other types of ulcers: the recommended dose is 400 mg of deproteinized hemoderivative from calf blood (10 ml of Actovegin injection solution), administered intravenously or 200 mg of deproteinized hemoderivative from calf blood (5 ml of Actovegin injection solution) administered intramuscularly,
daily or several times a week, depending on the evolution of the healing process, possibly associated with topical treatment with Actovegin.
Prophylaxis and treatment of skin-mucosal lesions induced by irradiation: the recommended dose is 200 mg of deproteinized hemoderivative from calf blood (5 ml of Actovegin injection solution) administered intravenously, daily during the irradiation period.
Treatment of radiogenic cystitis: the recommended dose is 400 mg of deproteinized calf blood hemoderivative (10 ml of Actovegin injection solution) administered daily, transurethral, ​​in combination with antibiotic therapy.
If you have any further questions on this product, ask your doctor, pharmacist or nurse.
Composition:
- The active substance is deproteinized calf blood hemoderivative. 5 ml of injection solution contain deproteinized calf blood hemoderivative (expressed as dry matter) 200 mg in the form of a 1113 mg concentrated solution.
- The other ingredients are: water for injections, 1M hydrochloric acid.
Presentation: 5 injections / box